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Objectives We assessed the incidence, predictors, and outcomes of gastrointestinal bleeding (GIB) in patients with acute
coronary syndromes (ACS).
Background GIB is a potential hemorrhagic complication in patients with ACS treated with antithrombotic and/or antiplatelet
medications. The clinical outcomes associated with GIB in this setting have not been systematically studied.
Methods In the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial, 13,819 patients with
moderate- and high-risk ACS, enrolled at 450 centers in 17 countries between August 2003 and December
2005, were randomized to the open-label use of 1 of 3 antithrombin regimens (heparin plus a glycoprotein
IIb/IIIa inhibitor, bivalirudin plus a glycoprotein IIb/IIIa inhibitor, or bivalirudin monotherapy).
Results GIB within 30 days occurred in 178 patients (1.3%). Older age, baseline anemia, longer duration of study drug
administration before angiogram, smoking, ST-segment deviation 1 mm, and diabetes were identified as inde-
pendent predictors of GIB. On multivariable analysis, GIB was strongly associated with 30-day all-cause mortality
(hazard ratio [HR]: 4.87 [interquartile range (IQR) 2.61 to 9.08], p  0.0001), cardiac mortality (HR: 5.35 [IQR
2.71 to 10.59], p  0.0001), and composite ischemia (HR: 1.94 [IQR 1.14 to 3.30], p  0.014), as well as with
1-year all-cause mortality (HR: 3.97 [IQR 2.64 to 5.99], p  0.0001), cardiac mortality (HR: 3.77 [IQR 2.14 to
6.63], p  0.0001), myocardial infarction (HR: 1.74 [IQR 1.01 to 3.02], p  0.047), and composite ischemia
(HR: 1.90 [IQR 1.37 to 2.64], p  0.0001). Patients who experienced GIB had significantly higher rates of stent
thrombosis compared with patients without GIB (5.8% vs. 2.4%, p  0.009).
Conclusions GIB is a serious condition in the scenario of ACS and is independently associated with mortality and ischemic
complications. (J Am Coll Cardiol 2009;54:1293–302) © 2009 by the American College of Cardiology Foundation
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Gastrointestinal Bleeding in ACS September 29, 2009:1293–302Gastrointestinal bleeding (GIB)
is one of the common sources of
hemorrhage in conservatively
treated patients with acute coro-
nary syndromes (ACS) and in
patients undergoing elective or
urgent percutaneous coronary in-
tervention (PCI) (1,2). Even in
nonselected populations, GIB re-
sults in high rates of morbidity and
mortality (3,4). The data are
scarce, however, regarding the spe-
cific implications of GIB in patients
with ACS whose contemporary
management typically includes a
combination of antithrombotic
and antiplatelet therapy (5,6).
We, therefore, examined the
atabase from the large, multicenter, randomized ACUITY
Acute Catheterization and Urgent Intervention Triage
trategy) trial to analyze the incidence, predictors and
utcomes of GIB occurring within 30 days after random-
zation in moderate- to high-risk patients with ACS.
ethods
tudy design. Design, inclusion and exclusion criteria, and
rincipal results of the ACUITY trial have been reported in
etail elsewhere (7–9). In brief, eligible patients were
andomized to the open-label use of 1 of 3 antithrombin
egimens started prior to angiography: heparin plus a
lycoprotein IIb/IIIa inhibitor (GPI), bivalirudin plus a
PI, or bivalirudin monotherapy. Patients assigned to
eparin plus a GPI or bivalirudin plus a GPI were random-
zed again in a 2  2 factorial design to routine upstream
PI started in all patients immediately after randomization
ersus deferred selective GPI initiation in the catheteriza-
ion laboratory only after diagnostic angiography identified
hich patients would undergo immediate PCI (7).
After mandatory angiography performed within 72 h of
andomization, the patients were triaged according to phy-
ician discretion to management by PCI, coronary artery
ypass grafting (CABG), or medical therapy. Aspirin 300 to
25 mg orally (PO) or 250 to 500 mg intravenously (IV) was
dministered daily during the index hospitalization, and 75
o 325 mg daily was prescribed indefinitely after discharge.
he initial dosing and timing of clopidogrel were left to
hysician discretion per local standards, although a 300-mg
r greater loading dose was required in all cases within 2 h
f PCI. Clopidogrel 75 mg daily was recommended for 1
ear in all patients with coronary artery disease.
linical end points. The primary end point in the ACUITY
rial was composite ischemia (death from any cause, myo-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass grafting
GIB  gastrointestinal
bleeding
GPI  glycoprotein IIb/IIIa
inhibitor
IQR  interquartile range
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TIMI  Thrombolysis In
Myocardial Infarctionardial infarction [MI], or unplanned revascularization for cschemia), major bleeding not related to CABG, and net
linical outcomes (composite ischemia or major bleeding)
7). The 30-day end points were measured as cumulative
vents occurring within 25 to 35 days after randomization.
ajor bleeding was intracranial or intraocular hemorrhage,
ematoma 5 cm in diameter, access site hemorrhage
equiring intervention, reoperation for bleeding, clinically
vert bleeding resulting in a decrease in hemoglobin by 3
/dl, reduction in hemoglobin concentration of 4 g/dl
ithout an overt source of bleeding, or the use of any blood
roduct transfusion (7). The definitions of other individual
rimary end points have been described (7–9). Bleeding
vents were also stratified using Thrombolysis In Myocar-
ial Infarction (TIMI) classification (10).
Gastrointestinal bleeding was defined as an episode of
offee ground emesis, hematemesis, melena, or red blood
er rectum occurring within 25 to 35 days after randomiza-
ion and documented by a treating physician in the patient’s
riginal source documents. Anemia was defined as a base-
ine hematocrit value 39% for men and 36% for women
11). Chronic renal insufficiency was defined as creatinine
learance 60 ml/min (12). Acquired thrombocytopenia
as defined as a nadir in-hospital platelet count 150
109/l in patients whose admission platelet count was
150  109/l and was further subdivided into mild,
oderate, severe, and profound when nadir platelet counts
ere 100 to 150, 50 to 100, 20 to 50, and 20  109/l,
espectively. Stent thrombosis was adjudicated based on
cademic Research Consortium (ARC) criteria (13).
A clinical events committee blinded to treatment
ssignment adjudicated all end point events using original
ource documents. The study was conducted according to
he Declaration of Helsinki and was approved by the
nstitutional review board or ethics committee at each
articipating center; all patients provided written informed
onsent.
tatistical analysis. Categorical variables were compared
ith chi-square tests or the Fisher exact test where appro-
riate. Continuous variables are presented as medians with
nterquartile ranges (IQRs) and were compared using the
ruskal-Wallis test. The 30-day and 1-year outcomes are
resented as Kaplan-Meier percentages and compared using
og-rank tests. Multivariable logistic regression was used to
dentify independent predictors of GIB. The independent
ssociation of the occurrence of GIB and subsequent mor-
ality, cardiac mortality, MI, composite ischemia, and stent
hrombosis within the 1-year follow-up period was exam-
ned using Cox proportional hazards models in which GIB
as treated as a time-dependent covariate. All multivariable
odels controlled for the following baseline covariates: age,
ex, diabetic status, hypertension, current smoking, prior
I, prior CABG, prior PCI, baseline cardiac biomarker
levation, ST-segment deviation, chronic renal insuffi-
iency, baseline anemia, treatment with heparin before
r
r
m
a
s
R
S
A
G
B
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September 29, 2009:1293–302 Gastrointestinal Bleeding in ACSandomization, randomization to 1 of the antithrombotic
egimens, triage to PCI versus CABG versus medical
anagement, and time from study drug administration to
ngiogram. A forward stepwise algorithm was used to select
ignificant covariates from this list.
aseline Clinical Data, Randomization Assignment, and Triage StraTable 1 Baseline Clinical Data, Randomization Assignment, an
Characteristics With GIB
Age, yrs 70.00 (60
Male sex 112/17
Weight, kg 83.00 (72
Diabetes 62/17
Treated with insulin 25/17
Hypertension 128/17
Hyperlipidemia 94/17
Current smoker 49/17
Previous myocardial infarction 63/17
Previous PCI 62/17
Previous CABG 31/17
Baseline hemoglobin, g/dl 13.20 (11
Baseline hematocrit, % 39.00 (35
Baseline anemia 69/16
Baseline serum creatinine, mg/dl 1.06 (0.8
Creatinine clearance, ml/min 73.51 (51
Baseline renal insufficiency 54/16
Baseline cardiac biomarker elevation 108/16
ST-segment deviation 1 mm 71/17
TIMI risk score
Low (0–2) 19/15
Intermediate (3–4) 74/15
High (5–7) 66/15
Antithrombin medications
Pre-randomization 119/17
Unfractionated heparin 61/17
Low molecular weight heparin 60/17
Post-randomization/pre-angiography
Bivalirudin 103/17
Unfractionated heparin 37/17
Enoxaparin 36/17
Glycoprotein IIb/IIIa inhibitors
Pre-angiography 82/17
Eptifibatide 56/17
Tirofiban 26/17
Abciximab 0/17
During PCI 83/17
Eptifibatide 57/17
Tirofiban 15/17
Abciximab 11/17
Time from study drug administration to angiogram, h 7.80 (1.5
Treatment strategy
PCI 107/17
Drug-eluting stent 66/10
Bare-metal stent 46/10
Drug-eluting and bare-metal stent 10/10
CABG 28/17
Medical management 43/17alues are median (interquartile range) or n (%).
CABG  coronary artery bypass grafting; GIB  gastrointestinal bleeding; PCI  percutaneous coronaresults
tudy population. Among a total of 13,819 patients with
CS enrolled at 450 sites in 17 countries in the ACUITY trial,
IB within 30 days of randomization occurred in 178 patients
in Patients With and Without GIBge Strategy in Patients With and Without GIB
Patients
p Value78) Without GIB (n  13,641)
.00) 63.00 (54.00–71.00) 0.0001
9) 9,550/13,641 (70.0) 0.048
.07) 83.99 (73.00–95.00) 0.27
0) 3,790/13,532 (28.0) 0.043
1) 1,168/13,532 (8.6) 0.015
9) 9,084/13,569 (66.9) 0.17
1) 7,653/13,363 (57.3) 0.28
7) 3,894/13,380 (29.1) 0.74
6) 4,159/13,311 (31.2) 0.14
2) 5,258/13,507 (38.9) 0.35
4) 2,434/13,596 (17.9) 0.92
.50) 14.10 (13.00–15.10) 0.0001
.60) 41.40 (38.20–44.10) 0.0001
6) 2,642/12,763 (20.7) 0.0001
0) 1.00 (0.82–1.16) 0.002
.35) 87.05 (65.65–112.62) 0.0001
1) 2,414/12,777 (18.9) 0.0001
3) 7,444/12,551 (59.3) 0.077
9) 4,754/13,626 (34.9) 0.18
9) 1,902/12,078 (15.7) 0.23
5) 6,602/12,078 (54.7) 0.045
5) 3,574/12,078 (29.6) 0.002
9) 8,743/13,641 (64.1) 0.48
3) 5,577/13,641 (40.9) 0.08
7) 3,465/13,641 (25.4) 0.015
9) 8,794/13,641 (64.5) 0.07
8) 2,317/13,641 (17.0) 0.19
2) 2,183/13,641 (16.0) 0.15
1) 4,502/13,641 (33.0) 0.0004
5) 2,897/13,641 (21.2) 0.002
6) 1,571/13,641 (11.5) 0.19
) 34/13,641 (0.2) 1.00
6) 5,151/13,641 (37.8) 0.012
0) 3,176/13,641 (23.3) 0.01
) 1,010/13,641 (7.4) 0.56
) 968/13,641 (7.1) 0.77
63) 3.80 (1.02–18.33) 0.002
1) 7,682/13,641 (56.3) 0.32
7) 4,748/7,682 (61.8) 1.00
0) 2,909/7,682 (37.9) 0.32
) 540/7,682 (7.0) 0.34
7) 1,511/13,641 (11.1) 0.06
2) 4,448/13,641 (32.6) 0.016tegyd Tria
(n  1
.00–76
8 (62.
.00–93
7 (35.
7 (14.
8 (71.
7 (53.
7 (27.
2 (36.
6 (35.
8 (17.
.90–14
.20–42
6 (41.
8–1.3
.85–94
3 (33.
3 (66.
8 (39.
9 (11.
9 (46.
9 (41.
8 (66.
8 (34.
8 (33.
8 (57.
8 (20.
8 (20.
8 (46.
8 (31.
8 (14.
8 (0.0
8 (46.
8 (32.
8 (8.4
8 (6.2
0–22.
8 (60.
7 (61.
7 (43.
7 (9.3
8 (15.
8 (24.y intervention; TIMI  Thrombolysis In Myocardial Infarction.
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Gastrointestinal Bleeding in ACS September 29, 2009:1293–3021.3%), including 107 of 7,789 (1.4%) patients triaged to PCI,
8 of 1,539 (1.8%) patients triaged to CABG, and 43 of 4,491
1.0%) patients triaged to medical management. Rates of GIB
ere the highest in patients randomized to heparin plus a GPI
1.5%) followed by bivalirudin plus a GPI (1.4%) and bivaliru-
in monotherapy (0.9%) (p  0.019). The incidence of GIB
ncreased with age from 0.57% in patients50 years of age to
.95%, 1.13%, 1.87%, and 3.54% in patients50 to60,60
o 70, 70 to 80, and 80 years of age, respectively.
A total of 48.2% of patients with GIB versus 4.1% of
atients without GIB met ACUITY protocol criteria for
ajor bleeding not related to CABG (p 0.0001), whereas
IMI major bleeding criteria were met in 19.8% versus
.2% of the patients, respectively (p  0.0001).
Clinical and procedural characteristics of patients who
eveloped GIB versus patients without GIB are shown in
able 1. Patients who developed GIB were older and more
requently female, and had higher rates of diabetes mellitus,
ncluding a higher prevalence of insulin-treated diabetes,
orse renal function, anemia, and higher TIMI risk scores.
he occurrence of GIB was associated with higher rates of
ow molecular weight heparin administration before coro-
ary angiography and GPI before angiography and during
CI, longer duration of study drug administration before
erformance of angiogram, and with triage to revasculariza-
ion with either PCI or CABG (75.8% vs. 67.4%, respec-
ively, p  0.016) rather than medical therapy.
ndependent predictors of GIB. As shown in Table 2,
ultivariable predictors of GIB in the entire study population
ncluded older age, baseline anemia, longer duration of study
rug administration before angiogram, smoking, ST-segment
ultivariable Predictors of GIB in the Entire ACUITY Population and inTable 2 Multivariable Predictors of GIB in the Entire ACUITY Popu
Multivariable Predictors
All patients
Age (per 10-yr increase)
Baseline anemia
Time from study drug administration to angiogram (per 10-h increase)
ST-segment deviation 1 mm
Current smoker
Diabetes mellitus
Randomization to bivalirudin monotherapy (versus heparin  glycoprotein IIb/IIIa
Patients triaged to PCI
Age (per 10-yr increase)
Baseline anemia
Diabetes mellitus
Current smoker
Time from study drug administration to angiogram (per 10-h increase)
Randomization to bivalirudin  glycoprotein IIb/IIIa (vs. heparin 
glycoprotein IIb/IIIa)
Patients triaged to CABG
Age (per 10-yr increase)
Patients triaged to medical management
Renal insufficiency
Baseline anemia
Time from study drug administration to angiogram (per 10-h increase)CUITY  Acute Catheterization and Urgent Intervention Triage Strategy; other abbreviations as in Tableeviation 1 mm, and diabetes. In patients triaged to PCI,
ultivariable predictors of GIB included older age, baseline
nemia, diabetes, smoking, and longer duration of study drug
dministration before angiogram. Randomization to bivaliru-
in monotherapy compared with randomization to heparin
lus a GPI showed a trend toward lower risk of GIB in the
ntire study population, especially in the PCI cohort. Older age
as the only independent predictor of GIB in patients triaged
o CABG. In patients triaged to medical management, time
rom study drug administration to angiogram, chronic renal
nsufficiency, and baseline anemia were independent predictors
f GIB.
utcomes of patients with GIB. Patients with GIB com-
ared with patients without GIB had a higher frequency of
cquired thrombocytopenia (21.6% vs. 10.5%, p 0.0001) due
o a higher incidence of mild (14.7% vs. 8.4%, p 0.003) and
oderate thrombocytopenia (6.3% vs. 1.8%, p  0.0001), but
ot severe or profound thrombocytopenia (0.6% vs. 0.3%, p
.61). A hemoglobin drop of 3 g/dl during index hospital-
zation occurred in 30.4% versus 1.3% of the patients with and
ithout GIB, respectively (p  0.0001). As expected, rates of
lood product transfusion not related to CABG were signifi-
antly higher in patients with versus without GIB (39.2% vs.
.8%, p 0.0001). The index hospitalization was significantly
onger in patients who experienced GIB compared with those
ho did not (6.0 days [IQR 4.0 to 10.0 days] vs. 3.0 days [IQR
.0 to 6.0 days], p  0.0001).
As shown in Figures 1 and 2, in the entire study population,
t 30-day and 1-year follow-up, GIB was associated with
ignificantly increased rates of all-cause mortality, cardiac
ortality, and nonfatal MI resulting in notably higher rates of
ents Triaged to PCI, CABG, or Medical Managementn and in Patients Triaged to PCI, CABG, or Medical Management
efficient Standard Error Odds Ratio 95% Confidence Interval p Value
0.4739 0.0897 1.61 1.35–1.92 0.0001
0.7182 0.1884 2.05 1.42–2.97 0.0001
0.1311 0.0405 1.14 1.05–1.23 0.0012
0.5809 0.2378 1.79 1.12–2.85 0.015
0.5500 0.2154 1.73 1.14–2.64 0.011
0.3747 0.1863 1.46 1.01–2.10 0.044
0.3290 0.1992 0.72 0.49–1.06 0.098
0.4161 0.1123 1.52 1.22–1.89 0.0002
0.7488 0.2362 2.12 1.33–3.36 0.002
0.6232 0.2283 1.87 1.19–2.92 0.006
0.5620 0.2691 1.75 1.04–2.97 0.037
0.1120 0.0540 1.12 1.01–1.24 0.0038
0.4094 0.2227 1.51 0.97–2.33 0.066
0.6854 0.2206 1.99 1.29–3.06 0.002
1.1490 0.4377 3.16 1.34–7.44 0.009
0.9973 0.4422 2.71 1.14–6.45 0.024
0.2754 0.0748 1.32 1.14–1.53 0.0002Patilatio
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September 29, 2009:1293–302 Gastrointestinal Bleeding in ACSomposite ischemia. Rates of urgent revascularization were not
nfluenced by GIB.
By multivariable analysis, GIB was an independent pre-
ictor of 30-day all-cause mortality (hazard ratio [HR]: 4.87
IQR 2.61 to 9.08], p  0.0001), cardiac mortality (HR:
.35 [IQR 2.71 to 10.59], p  0.0001), and composite
schemia (HR: 1.94 [IQR 1.14 to 3.30], p  0.014). At
-year follow-up, this relationship continued to be signifi-
ant, and GIB was also a predictor of myocardial infarc-
ion (Fig. 3).
utcomes of patients with GIB in relation to triaged
reatment. The negative impact of GIB on rates of death,
I, and composite ischemia was consistent across patients
Figure 1 Ischemic Events at 30 Days and 1 Year in Patients W
Patients with versus without gastrointestinal bleeding (GIB) have significantly incre
1-year (B) rates of cardiac and all-cause mortality, myocardial infarction, and compriaged to PCI and medical treatment (Table 3). In patients
riaged to CABG, the occurrence of GIB also resulted in
igher all-cause and cardiac mortality at 30 days and 1 year,
hereas rates of nonfatal MI were unrelated to GIB.
tent thrombosis. Among 7,789 patients triaged to PCI,
tent thrombosis (definite, probable, or possible) developed
ithin 1 year in 6 of 107 (5.8%) patients with GIB and 161
f 7,682 (2.4%) patients without GIB (p  0.009). All 6
ases of stent thrombosis (1 definite and 5 probable) in the
IB group occurred within 35 days of randomization. Five
f these cases were fatal, including 3 patients who died
uring the index hospitalization (no information is available
oncerning whether antiplatelet therapy was continued after
nd Without GIB
0-day (A) and
ischemic outcome.ith a
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Gastrointestinal Bleeding in ACS September 29, 2009:1293–302IB episodes in these patients) and 2 patients who died
fter discharge (both were prescribed dual antiplatelet ther-
py at discharge). The only patient with GIB who survived
n episode of stent thrombosis was prescribed a thienopy-
idine, but not aspirin, at discharge.
edication use. Medications at admission did not differ
ignificantly between patients with and without GIB
Table 4). At discharge and 30-day and 1-year follow-up,
atients with GIB were significantly less likely to be treated
ith aspirin than those without GIB. Daily dosages of
spirin at discharge were similar between the 2 groups.
reatment with thienopyridines at discharge, 30 days, and 1
Figure 2 Cumulative Risk of All-Cause and Cardiac Death in Pa
By Kaplan-Meier estimates, patients with versus without gastrointestinal bleedingear was also less likely in patients with versus without GIB. Mowever, the difference was significant only at discharge.
ther medications at follow-up, including beta-blockers,
tatins, and angiotensin-converting enzyme inhibitors or
eceptor blockers, did not differ significantly between the 2
roups.
iscussion
he major results of this analysis are: 1) GIB within 30 days
f randomization occurred in 1.3% of moderate- and
igh-risk patients with ACS, and was associated with
trikingly increased rates of early and late mortality, nonfatal
s With and Without GIB
ad significantly higher all-cause (A) and cardiac (B) death at 1 year.tient
(GIB) hI, stent thrombosis, acquired mild or moderate thrombo-
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September 29, 2009:1293–302 Gastrointestinal Bleeding in ACSytopenia, need for blood product transfusions, and pro-
onged in-hospital stay; 2) older age, baseline anemia, longer
uration of study drug administration before angiogram,
moking, ST-segment deviation 1 mm, and diabetes were
trongly related to GIB within 30 days of randomization;
nd 3) aspirin and/or thienopyridine withdrawal was fre-
uent among patients experiencing GIB, resulting in one-
ourth of patients not receiving aspirin and almost one-half
f patients not receiving thienopyridines at discharge.
In the ACUITY trial, GIB was the second most frequent
ource of non–CABG-related bleeding after access site
leeding in the entire study population, and was the most
ommon source of bleeding among patients triaged to
edical management. As patients with hemorrhagic diathe-
es and recent bleeding were excluded from the ACUITY
rial, the true incidence of GIB in a nonselected ACS
opulation is likely to be higher given the increasing incidence
f GIB as the population ages. In 1 retrospective analysis of
onsecutive patients with ACS treated with a combination of
spirin, clopidogrel, and enoxaparin, rates of GIB were
.7% (5).
Outcomes of patients with ACS experiencing GIB are
ypically poor. In this analysis, index hospitalization was
Figure 3 Multivariable Predictors of 1-Year Individual and Comp
Gastrointestinal bleeding was an independent predictor of 1-year all-cause mortalit
end point. CABG  coronary artery bypass grafting; CI  confidence interval; HR wice as long in patients who experienced GIB compared (ith those who did not. Patients who developed GIB had
xtremely high rates of mortality and MI. Specifically, 9.6%
f the patients who had GIB died within 35 days, with the
ajority of these patients (77%) dying from cardiac causes.
ive of 6 patients who had GIB and probable/definite stent
hrombosis died. At 1 year, around one-fifth of patients
ith GIB had died, one-half from a cardiac cause; cardiac
ortality in patients with GIB nearly doubled; and more
han one-third had died or experienced a nonfatal MI or an
nplanned revascularization. In this analysis, 1-year mortal-
ty in patients experiencing GIB was almost 2-fold higher
ompared with a combined unstable angina/ACS popula-
ion of 5,673 patients undergoing PCI from a large case-
ontrolled Australian study (6). In the same study, patients
ith ACS had an approximately 5-fold increase in the
dds of GIB compared with patients with stable coronary
yndromes.
The mechanisms behind the high rates of mortality and
onfatal MI in patients with ACS experiencing GIB are
ultifactorial. These patients had a more unfavorable base-
ine clinical profile that included older age, higher preva-
ence of diabetes, anemia, and chronic renal insufficiency, all
actors known to worsen the prognosis of patients with ACS
Ischemic End Point
iac mortality, myocardial infarction, and the composite ischemic
rd ratio; MI  myocardial infarction; PCI  percutaneous coronary intervention.osite
y, card
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Gastrointestinal Bleeding in ACS September 29, 2009:1293–302rovoke or aggravate ischemia, resulting in adverse clinical
utcomes. Patients with GIB are commonly treated with
lood product transfusion, as happened with more than
ne-third of the patients in this analysis. Although no
andomized trial has prospectively assessed the impact of
lood transfusion on outcomes in patients with ACS,
nalyses from large retrospective series have provided evi-
ence that transfusion may be harmful (18,19). In this
nalysis, occurrence of GIB correlated with higher incidence
f thrombocytopenia, which is also known to worsen the
rognosis of patients with ACS (20). The retrospective
ature of this study does not allow us to identify the exact
echanisms of thrombocytopenia that might be related to
he higher rates of treatment with GPI in patients who
eveloped GIB or to administration of heparin resulting in
eparin-induced thrombocytopenia with/without thrombo-
is. Gastrointestinal bleeding is a well-known cause of
remature cessation of antiplatelet therapy, which poses
dditional risk for ischemic outcomes in patients with
CS (1,21,22). In this analysis, one-fifth (20.8%) of the
atients with GIB were not taking either aspirin or thien-
pyridines at discharge. The percentage of patients not on
spirin or thienopyridines was highest among patients
riaged to medical management (40.0%), followed by pa-
ients triaged to CABG (27.3%) and to PCI (13.3%). Of
ote, in the ACUITY trial, aspirin was recommended at a
elatively high daily dosage (300 to 325 mg PO or 250 to
00 mg IV) during index hospitalization. Although aspirin
t any dosage is known to be ulcerogenic, an escalating dose
s related to a higher incidence of GIB (23). The optimal
osage of aspirin in ACS is still not known and is being
0-Day and 1-Year Clinical Outcomes of Patients With and WithoutTable 3 30-Day and 1-Year Clinical Outcomes of Patients With
Events
Patients Triaged to PCI
GIB
(n  107)
No GIB
(n  7,682) p Value
At 30 days
Death 8.4 (9) 1.0 (73) 0.0001
Cardiac death 6.6 (7) 0.8 (63) 0.0001
Myocardial infarction 15.1 (16) 6.1 (470) 0.0002
Q-wave 3.8 (4) 1.0 (77) 0.005
Non–Q-wave 11.3 (12) 5.2 (395) 0.005
Unplanned revascularization 6.8 (7) 3.4 (260) 0.63
Composite ischemic end point 21.5 (23) 8.7 (666) 0.0001
At 1 yr
Death 22.1 (22) 3.3 (225) 0.0001
Cardiac death 14.0 (13) 1.8 (130) 0.0001
MI 20.1 (21) 8.9 (661) 0.0001
Q-wave 4.8 (5) 1.7 (118) 0.008
Non–Q-wave 16.6 (17) 7.3 (548) 0.0002
Unplanned revascularization 15.8 (15) 12.6 (913) 0.28
Composite ischemic end point 37.6 (40) 19.6 (1425) 0.0001
alues are % (n).
Abbreviations as in Table 1.nvestigated in an ongoing trial (24). tConsistent with previous reports, in this analysis, occur-
ence of GIB was strongly associated with older age,
nemia, and smoking (25–27). A novel and an important
ractical finding of this study is that the duration of
ntithrombotic therapy before angiography was more than
oubled in patients with GIB compared with patients
ithout GIB. By multivariable analysis, there was a 12%
ncrement in odds of GIB per 10-h increase in duration of
ntithrombotic medications. To reduce the incidence of
IB and perhaps other bleeding complications, this time
hould be shortened in ACS patients at high risk for
leeding.
Concern is warranted regarding treatment with heparin
lus a GPI, which by multivariable analysis was associated
ith a trend toward a higher incidence of GIB compared
ith bivalirudin monotherapy across the entire ACUITY
opulation, especially in patients triaged to PCI. Although
PI are known to increase access site–related bleeding in
atients treated with PCI, an increased incidence of GIB
as not been reported in any of the pivotal trials assessing
afety and efficacy of different GPIs in the setting of PCI
28–30) or conservative treatment (31,32). Still, in the
andomized REPLACE-2 (Randomized Evaluation of PCI
inking Angiomax to Reduced Clinical Events) trial, GIB
ccurred significantly more often in patients randomized to
eparin plus a GPI compared with patients randomized to
ivalirudin (0.6% vs. 0.1%, p 0.003) (2). It is also possible
hat rates of GIB may vary with different types of GPI. In
large regional registry of contemporary PCI, treatment
ith abciximab as opposed to eptifibatide was associated
ith a higher incidence of GIB in patients treated with
rimary PCI (4.8% vs. 2.8%, p  0.01) (33). The results of
Triaged to PCI, CABG, or Medical ManagementWithout GIB Triaged to PCI, CABG, or Medical Management
Patients Triaged to CABG Patients Triaged to Medical Treatment
IB
28)
No GIB
(n  1,511) p Value
GIB
(n  43)
No GIB
(n  4,448) p Value
3 (4) 3.8 (57) 0.004 9.6 (4) 1.4 (62) 0.0001
0 (3) 3.7 (56) 0.052 7.1 (3) 1.0 (43) 0.0001
9 (3) 11.6 (174) 0.89 5.0 (2) 0.9 (40) 0.009
3 (2) 3.5 (53) 0.30 2.6 (1) 0.2 (8) 0.001
4 (2) 8.1 (121) 0.86 2.5 (1) 0.7 (32) 0.21
0 (0) 1.5 (23) 0.52 2.5 (1) 1.2 (52) 0.46
4 (6) 14.8 (224) 0.38 14.4 (6) 3.0 (133) 0.0001
0 (7) 6.4 (95) 0.0001 19.4 (8) 4.1 (167) 0.0001
0 (3) 4.9 (73) 0.14 12.3 (5) 2.3 (92) 0.0001
9 (3) 12.4 (184) 0.82 7.8 (3) 2.7 (112) 0.036
3 (2) 3.6 (54) 0.31 5.4 (2) 0.4 (18) 0.0001
4 (2) 8.9 (132) 0.77 2.5 (1) 2.3 (96) 0.85
3 (1) 4.2 (61) 0.96 8.2 (3) 4.3 (174) 0.19
7 (10) 19.8 (296) 0.048 26.6 (11) 9.3 (388) 0.0001GIBand
G
(n 
14.
11.
10.
7.
7.
0.
21.
25.
11.
10.
7.
7.
4.
35.his analysis coupled with the data from the REPLACE-2
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September 29, 2009:1293–302 Gastrointestinal Bleeding in ACSrial support the use of bivalirudin rather than heparin plus
GPI in patients with ACS at high risk for GIB.
tudy limitations. The ACUITY trial was not specifically
owered to evaluate the predictors and clinical outcomes of
IB. Nonetheless, GIB was rigorously defined in the protocol,
nd all bleeding and end point data were prospectively col-
ected and adjudicated by an independent Clinical Event
ommittee that was blinded to randomized treatment assign-
ent. Given the post hoc nature of this analysis, data are
acking on the specific causes and management of GIB. Even
y multivariable analysis, GIB was strongly associated with
ortality and the composite ischemic end point; however, no
efinite conclusion may be drawn with regard to GIB as a
irect cause of these events. Information on other drugs known
o increase the risk of GIB, including warfarin, nonsteroidal
nti-inflammatory drugs, corticosteroids, selective serotonin
euptake inhibitors, and spironolactone, was not collected.
his analysis also lacks data on treatment with proton pump
nhibitors. Although their efficacy for the secondary prevention
f upper GIB was confirmed in randomized controlled trials
34,35), no study has prospectively assessed the safety and
fficacy of this therapy in the primary prevention of upper GIB.
oreover, recent evidence suggests that proton pump inhibi-
Medication Use at Different Time Intervals in PaTable 4 Medication Use at Different Time In
Patients With G
(n  178)
At admission
Aspirin 123/178 (69.1
Thienopyridine 44/178 (24.7
ACE inhibitor or ARB 81/178 (45.5
Beta-blocker 89/178 (50.0
Statin 76/178 (42.7
At discharge
Aspirin 126/168 (75.0
Daily dosage, mg
100 69/166 (41.6
100–200 11/166 (6.6)
200–300 12/166 (7.2)
300 74/166 (44.6
Thienopyridine 98/168 (58.3
Aspirin or thienopyridine 133/168 (79.2
At 30 days
Aspirin 140/163 (85.9
Thienopyridine 100/163 (61.3
ACE inhibitor or ARB 94/163 (57.7
Beta-blocker 121/163 (74.2
Statin 128/163 (78.5
At 1 yr
Aspirin 110/144 (76.4
Thienopyridine 56/144 (38.9
ACE inhibitor or ARB 81/145 (55.9
Beta-blocker 102/144 (70.8
Statin 103/144 (71.5
Values are n/N (%).
ACE  angiotensin-converting enzyme; ARB  angiotensin receptorors may decrease clopidogrel’s inhibitory effect on platelet
E2Y12 receptors and are associated with a higher risk of
dverse outcomes after ACS (36,37). Additional clinical mea-
urements not included in this analysis (e.g., certain comor-
idities) may also have interacted with GIB. By study protocol,
leeding events occurring after 30-day follow-up were not
ollected, nor was the timing of discontinuation of aspirin
nd/or thienopyridines.
onclusions
IB, even at a level that does not meet the definition of
ajor bleeding, is a devastating condition in the setting of
CS and is associated with high rates of mortality, nonfatal
I, stent thrombosis, and prolonged hospitalization. Phy-
icians should be aware of GIB in high-risk populations,
ncluding the elderly, smokers, and patients with anemia.
iven the adverse prognostic significance of GIB, it should
e reported in any trial assessing the safety of new anti-
hrombotic agents and regimens.
eprint requests and correspondence: Dr. Eugenia Nikolsky,
irector, Academic Affairs, Cardiovascular Research Foundation,
11 East 59th Street, 11th Floor, New York, New York 10022.
s With and Without GIBls in Patients With and Without GIB
Patients Without GIB
(n  13,641) p Value
9,496/13,616 (69.7) 0.87
3,328/13,614 (24.4) 0.93
6,646/13,609 (48.8) 0.94
6,691/13,610 (49.2) 0.88
5,753/13,603 (42.3) 0.41
11,204/13,034 (86.0) 0.0002
5,163/12,796 (40.3) 0.75
753/12796 (5.9) 0.62
1,024/12796 (8.0) 0.89
5,856/12,796 (45.8) 0.81
8,570/13,034 (65.8) 0.049
11,827/13,034 (90.7) 0.0001
12,271/13,203 (92.9) 0.0018
8,989/13,203 (68.1) 0.076
7,851/13,200 (59.5) 0.69
10,124/13,201 (76.7) 0.46
10,600/13,202 (80.3) 0.55
11,332/12,855 (88.2) 0.0001
5,724/12,852 (44.5) 0.18
7,309/12,853 (56.9) 0.80
9,267/12,854 (72.1) 0.71
9,910/12,858 (77.1) 0.13
r; other abbreviations as in Table 1.tientterva
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